ANDREW C HARRIS portrait
  • Adjunct Assistant Professor, Pediatrics

Research Keywords

  • Identification and Clinical Application of Graft-Versus-Host-Disease (GVHD) Biomarkers
  • Post-Bone Marrow Transplant (BMT) Relapse Prevention and Management

Presentations

  • Hematopoietic Stem Cell Transplantation: Early Transplant Complications. Pediatric Pathology Grand Rounds for University of Utah/Primary Children's Hospital, Salt Lake City, Utah, United States. , Presented, 2019.
  • Harris AC. Prevention of Graft-vesus-Host Disease: Past, Present and Future. University of Utah, Utah Clinical Pharmacology Fellowship Program Distinguished Speakers Series, Salt Lake City, Utah. , , 2017.
  • Harris AC. Graft-Versus-Host Disease: Past, Present and Future. Primary Children’s Hospital, Heme/Onc/BMT Lecture Series, Salt Lake City, UT. , , 2015.
  • Harris AC. Biomarkers of Graft-Versus-Host Disease. University of Texas MD Anderson Cancer Center, Stem Cell Transplant Service Meeting, Houston, TX. , , 2012.
  • Andrew C. Harris. A Novel GVHD Prophylaxis Stratedgy Using Post-Transplant Cyclophosphamide and Extracorporeal Photopheresis.Children's Hospital of Colorado/Aspen Research Conference, Aspen, Colorado. , , 2016.
  • Levine J, Ozbek U, Rentereia A, Hartwell M, Major-Monfried H, Holler E, Pawarode A, Aziz M, Hogan W, Ayuk F, Efebera Y, Qayed M, Hexner E, Wudhikarn K, Wolfl M, Ordemann R, Mielke S, Bunworasate U, Devine S, Kröger N, Al-Malki M, Chen Y, Harris A, Jagasia A, Kitko C, Litzow M, Locatelli F, Nakamura R, Reddy P, Reshef R, Roesler W, Weber D, Yanik G, Ferrara J. A Biomarker Algorithm Predicts Non-Relapse Mortality Before GVHD, at Diagnosis, and During Treatment. Annural Meeting for the European Society for Blood and Marrow Transplantation. Marseille, France. , , 2017.

Languages

  • English, Fluent.

Publications

  • Harris AC, Boelens JJ, Ahn KW, Fei M, Abraham A, Artz A, Dvorak CC, Frangoul H, Freytes CO, Gale RP, Hong S, Lazarus HM, Mineishi S, Nishihori T, O'Brien T, Williams KM, Pasquini MC, Levine JE. (date unknown). Comparison of Outcomes for Myeloablative Conditioning Regimens Combining Busulfan with Either Cyclophosphamide or Fludarabine in Children. (pp. 664). Vol. 128. Accepted, .
  • Hartwell MJ, Ozbek U, Holler E, Renteria AS, Reddy PR, Aziz M, Hogan WJ, Ayuk FA, Efebera YA, Hexner EO, Bunworasate U, Qayed M, Ordemann R, Wolfl M, Mielke S, Pawarode A, Chen YB, Devine SM, Harris AC, Jagasia MH, Kitko CL, Litzow MR, Kroeger N, Locatelli F, Nakamura R, Reshef R, Roesler W, Weber D, Wudhikarn K, Yanik GA, Levine JE, Ferrara JLM. (date unknown). An Early Biomarker Algorithm Predicts Lethal Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation. (pp. 509). Vol. 128. Accepted, .
  • Major-Monfried H, Ozbek U, Renteria AS, Hartwell MJ, Pawarode A, Yanik GA, Ayuk FA, Holler E, Efebera YA, Hogan WJ, Qayed M, Hexner EO, Wudhikarn K, Wolfl M, Ordemann R, Mielke S, Bonwoasate U, Devine SM, Kroeger N, Al-Malki M, Chin YB, Harris AC, Jagasia MH, Kitko CL, Litzow MR, Locatelli F, Nakamura R, Reddy PR, Reshef R, Roesler W, Weber D, Ferrara J, Levine JE. (date unknown). Biomarkers Predict Graft-Vs-Host Disease Outcomes Better Than Clinicl Response After One Week of Treatment. (pp. 510). Vol. 128. Accepted, .
  • Harris AC, Young R, Devine SM, Hogan WJ, Ayuk F, Bunworasate U, Chanswangphuwana C, Efebara YA, Holler E, Litzow MR, Ordemann R, Qayed M, Renteria AS, Reshef R, Wolfl M, Chen YB, Goldstein S, Jagasia MH, Locatelli F, Miledke S, Porter DL, Schechter T, Shekhovtsova Z, Ferrara JLM, Levine JE. (date unknown). Guidelines for the Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: An International Consensus Report. (pp. 3154). Vol. 126. Accepted, .
  • Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller HK, Magenau JM, Weisdorf DJ, Ho VT, Bolanos-Meade J, Alousi AM, Ferrara JLM (date unknown). A biomarker algorithm defines onset grades of acute graft-vs-host disease with distinct non-relapse mortality; also presented orally at American Society of Hematolgy Annual Meeting, San Francisco, CA. (pp. 661). Vol. 124. Accepted, .
  • MacMillan ML, Robin M, Harris AC, Defor TE, Martin PJ, Alousi A, Ho VT, Bolanos-Meade J, Ferrara JLM, Jones RJ, Arora M, Blazar BR, Holtan SG, Jacobsohn D, Pasquini MC, Socie G, Antin JH, Levine JE, Weisdorf DJ (date unknown). A refined clinical risk score at onset of treatment for acute GVHD that predicts response to initial therapy, survival and transplant-related mortality; also presented orally at American Society of Hematolgy Annual Meeting, San Francisco, CA. (pp. 188). Vol. 124. Accepted, .
  • Vander Lugt MT, Braun T, Ferrara JLM, Hanash S, Levine J, Wang C, Zhang Q, Chin A, Harris AC, Choi SW, Couriel D, Reddy P, Paczesny S (date unknown). Plasma concentration of ST2, the IL33 receptor, at initiation of graft versus host disease therapy predicts day 28 response and day 180 survival post-treatment; also presented orally at American Society of Hematology Annual Meeting, San Diego, CA. (pp. 152). Vol. 118. Accepted, .
  • Grupp S, Hu ZH, Zhang Y, Keating A, Pulsipher MA, Philips C, Margossian SP, Rosenthal J, Salzberg D, Schiff DE, Yanik G, Curran KJ, Harris AC, Hematti P, Nikiforow S, Steinert P, Yi L, Chawla R, Horowitz MM, Bleickhardt E, Pasquini MC (date unknown). Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry. (pp. 2619). Vol. 134. Accepted, .
  • O'Brien MM, Ji L, Rheingold SR, Bhojwani D, Yi J, Shah NN, Yuan C, Harris AC, Brown P, Borowitz M, Militano O, Frausto EG, Blank C, Devidas M, Gore L, Loh M (date unknown). A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children’s Oncology Group Protocol AALL1621. (pp. 741). Vol. 134. Accepted, .
  • Cuvelier GD, Kariminia A, Nemecek ER, Kitko CL, Wahlstrom JT, Harris AC, Bittencourt H, Lewis VA, Pulsipher MA, Schechter T, Choi SW, Caywood EH, Bhatia M, Kasow KA, Jacobsohn DA, Oshrine B, Chaudhury S, Chewning JH, Flower A, Coulter D, Joyce M, Savasan S, Pawlowska AB, Megason GC, Mitchell D, Cheerva A, Lawitschka A, Ng B, Schultz KR (date unknown). Naïve Helper T Cell and Regulatory T and NK Cell Subsets are Associated with Pediatric Chronic Graft-Versus-Host Disease: Results of the ABLE / PBMTC 1202 Study. (pp. 11-12). Vol. 136. Accepted, .
  • Levine JE, Harris AC, Taylor A, Braun TM, Magenau J, Ferrara JLM (date unknown). A biomarker-based grading system at onset of GVHD predicts NRM better than the modified Glucksberg grading system; also presented orally at American Society of Hematology Annual Meeting, New Orleans, LA. (pp. 145). Vol. 122. Accepted, .
  • Vander Lugt MT, Braun TM, Hanash S, Ferrara JLM, Ritz J, Ho VT, Antin JH, Zhang Q, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel D, Reddy P, Paczesny S (date unknown). Plasma ST2 concentrations predict development of acute GVHD and non-relapse mortality; also presented orally at American Society of Hematology Annual Meeting, Atlanta, GA. (pp. 466). Vol. 120. Accepted, .
  • Harris AC, Ferrara JLM, Braun T, Couriel DR, Choi SW, Kitko C, Goldstein S, Magenau J, Paczesny S, Pawarode A, Reddy P, Yanik G, Taylor A, Connelly J, Byersdorfer C, Levine JE (date unknown). An algorithm combining clinical characteristics and day 7 biomarker concentrations predicts future GVHD following related donor hematopoietic cell transplantation; also presented orally at American Society of Hematology Annual Meeting, Atlanta, GA. (pp. 463). Vol. 120. Accepted, .
  • Paczesny S, Braun T, Vander Lugt M, Harris A, Fiema B, Hernandez J, Choi SW, Kitko C, Magenau J, Yanik G, Peres EM, Pawarode A, Mineishi S, Whitfield J, Jones D, Couriel DR, Reddy P, Hanash S, Ferrara JLM, Levine JE (date unknown). Three biomarker panel at days 7 and 14 can predict development of grade II-IV acute graft-versus-host disease; abstract presented orally at American Society of Hematology Annual Meeting, Orlando, FL. (pp. 675). Vol. 116. Accepted, .
  • Harris AC, Ferrara JLM, Greenson JK, Braun TM, Holler E, Teshima T,Levine JE, Choi SW, Huber E, Landfried K, Vander Lugt M, Reddy P, Zhang Q, Hanash S, Paczesny S (date unknown). A novel grading system of lower Gastrointestinal acute graft-versus-host disease at disease onset predicts response to therapy and non-relapse mortality; also presented orally at American Society of Hematology Annual Meeting, San Diego, CA. (pp. 153). Vol. 118. Accepted, .
  • Qayed M, Watkins B, Bratrude B, Betz K, Rhodes J, Sinclair S, Suessmuth Y, Yu A, Dean C, Cribbin K, Narayan A, Hunt D, Schwartz N, Hebert K, Pasquini M, Rogatko A, Tighiouart M, Kim S, Bresee C, Gillespie S, Davis J, Choi S, Duncan C, Giller R, Grimley M, Harris A, Hacobsohn D, Lalefar N, Norkin M, Pulsipher M, Shenoy S, Petrovic A, Schultz K, Blazar B, Langston A, Horan J, Kean L (date unknown). T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention in matched and mismatched unrelated donor transplantation: Results of the first phase 2 trial. (pp. 0100). Vol. 54. Accepted, .
  • Dietz AC, Grupp SA, Laetsch TW, Stefanski H, Myers GD, Bittencourt H, Buechner J, Nemecek ER, Martin PL, Hiramatsu H, Mechinaud F, Yanik GA, De Moerloose B, Wood PA, Rasouliyan L, Zhang Y, Thomas SK, Shah S, Harris A (date unknown). Patient-Reported Quality of Life (QOL) Following CTL019 in Pediatric and Young Adult Patients (pts) with Relapsed/Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL). (pp. 10523). Vol. 35. Accepted, .
  • Baruchel A, Grupp SA, Rives S, Boyer MW, Bittencourt H, Bader P, Beuchner J, Laetsch TW, Myers GD, Qayed M, Pulsipher MA, De Moerloose B, Hiramatsu H, Yanik GA, Stefanski HE, Davis KL, Driscoll T, Nemecek E, Peters C, Cota M, Shah S, Zhang J, Harris AC (date unknown). Improvement of patient-reported quality of life following tisagenlecleucel infusion in pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. (pp. 61-62). Vol. 2. Accepted, .
  • Shah NN, O'Brien MM, Yuan C, Ji L, Xu X, Rheingold SR, Bhojwani D, Uo J, Harris AC, Brown PA, Borowitz MJ, Devidas M, Raetz EA, Gore L, Loh ML (date unknown). Evaluation of CD22 Modulation as a Mechanism of Resistance to Inotuzumab Ozogamicin (InO): Results from Central CD22 Testing on the Children’s Oncology Group (COG) Phase 2 Trial of InO in Children and Young Adults with CD22+ B-Acute Lymphoblastic Leukemia (B-ALL). Accepted, .
  • Vander Lugt M, Braun T, Ferrara J, Hanash S, Levine J, Harris A, Couriel D, Paczesny S (date unknown). Plasma ST2 predicts therapy-resistant graft-versus-host disease and survival; also presented orally at American Association of Immunologists Annual Meeting 2012, Boston, MA. (pp. 126.13). Vol. 188. Accepted, .
  • Gomez A, Hammer SG, Braun T, Hanash S, Ferrara JLM, Greenson JK, Wang H, Zhang Q, Vander Lugt M, Pongtornpipat P, Mamiman K, Conlon M, Chang L, Choi SW, Levine JE, Harris A, Couriel DR, Reddy P, Paczesny P (date unknown). A novel CD4+CD146+CCR5+ T-cell population is a biomarker of intestinal graft-versus-host disease; also presented orally at 39th Annual Meeting of the European Group for Blood and Marrow Transplantation, London, UK. (pp. S66). Vol. 48. Accepted, .
  • Harris A, Ferrara JLM, Levine JE, Braun T, Hogan J, Crawford J, Pitteri S, Wang H, Chin A, Zhang Q, Granger J, Vander Lugt M, Byersdorfer C, Magenau J, Gomez A, Choi S, Kitko C, Yanik G, Peres E, Pawarode A, Mineishi S, Reddy P, Couriel DR, Hanash S, Paczesny S (date unknown). REG3α is a biomarker of gastrointestinal graft-versus-host disease. Accepted, .
  • Jacobsohn D, Loken M, Fei M, Adams A, Eidenschenk Brodersen L, Fritschle W, Logan B, Woo Ahn K, Shaw B, Kletzel M, Olszewski M, Kahn S, Keating A, Harris A, Teira P, Margossian S, Duerst R, Martin P, Boyer M, Nemecek E, Dvorak C, Petrovic A, Pulsipher M (date unknown). Minimal Residual Disease (MRD) pre‐ and post‐ HCT for children with AML is highly predictive of event‐free survival: A Pediatric Blood and Marrow Transplant Consortium Study. (pp. S371). Vol. 52. Accepted, .
  • Cuvelier GD, Nemecek E, Wahlstrom JT, Harris A, Pulsipher MA, Lewis V, Bittencourt H, Choi SW, Kitko CL, Caywood E, Bhatia M, Kasow KA, Jocobsohn J, Oshrine B, Kheradpour A, Chaudhury S, Chewning J, Schechter T, Flower A, Coulter D, Joyce M, Savasan S, Pawlowska A, Megason G, Mitchell D, Cheerva A, Karaminia A, Halevy A, Schultz KR (date unknown). Recent Thymic Emigrants and Tregs Expressing CD45RA and CD31 are Decreased at Day 100 and Prognostic for Chronic Graft-Versus-Host Disease in Children: Results from the Applied Biomarkers of Late Effects (ABLE) / Pediatric Blood and Marrow Transplant Consortium 1202 Study. (pp. S114-S115). Vol. 24. Accepted, .
  • Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H, Maganau J, Weisdorf DJ, Ho VT, Bolanos-Meade J, Alousi AM, Ferrara JLM, Blood and Marrow Transplant Clinical Trials Network (date unknown). A new Ann Arbor Grading System uses biomarkers to risk stratify patients for non relapse mortality and the onset of acute graft versus host disease; also presented orally at 40th Annual Meeting of the European Society for Blood and Marrow Transplantation, Milan, Italy. (pp. S3-4). Vol. 49. Accepted, .
  • Cuvelier GDE, Nemecek ER, Wahlstrom JT, Harris AC, Pulsipher MA, Lewis V, Bittencourt H, Choi SW, Kitko CL, Caywood E, Bhatia M, Kasow KA, Jacobsohn DA, Petrovic A, Kerhadpour A, Chaudhury S, Chewning JH, Schechter T, Abikoff C, Coulter DW, Joyce M, Savasan S, Pawlowska A, Megason G, Mitchell D, Cheerva A, Halevy A, Schultz KR (date unknown). Challenges with Diagnosing Pulmonary Chronic GVHD in Children as per the 2014 National Institutes of Health Consensus Criteria: Applied Biomarkers of Late Effects (ABLE)/Pediatric Blood and Marrow Transplant Consortium (PBMTC) 1202 Study. (pp. S74-S75). Vol. 23. Accepted, .
  • Watkins BW, Qayed M, Bratrude B, Betz K, Sinclair S, Suessmuth Y, Rhodes J, Yu A, Cribbin K, Dean C, Narayan A, Hunt D, Schwartz N, Hebert K, Pasquini MC, Rogatko A, Tighiouart M, Kim S, Bresee C, Banks A, Gillespie S, Choi S, Davis JH, Duncan CN, Giller R, Grimley MS, Harris AC, Jacobsohn DA, Lalefar NR, Norkin M, Pulsipher MA, Shenoy S, Petrovic A, Schultz KR, Blazar BR, Langston AA, Horan J, Kean LS (date unknown). T Cell Costimulation Blockade with CTLA4-Ig (Abatacept) for Acute Gvhd Prevention in HLA Matched and Mismatched Unrelated Donor Transplantation: Results of the First Phase 2 Trial. (pp. S51-S52). Vol. 25. Accepted, .
  • Zhao D, Kim YH, Greenson JK, Chaudhry MS, Hoepting M, Jeong S, Anderson ER, Harris AC, Levine JE, Ozbek U, Hooper LV, Stappenbeck TS, Ver Heul A, Lieu TC, Reddy P, Ferrara J (date unknown). Regenerating Islet-Derived 3-Alpha (REG3A) Protects the Intestinal Stem Cell Niche to Control Acute Gastrointestinal Graft-Versus-Host Disease. (pp. S47-S48). Vol. 24. Accepted, .
  • Harris AC, Ferrara JLM, Braun T, Couriel DR, Choi SW, Kitko C, Goldstein S, Magenau J, Paczesny S, Pawarode A, Reddy P, Yanik G, Taylor A, Connelly J, Byersdorfer C, Levine JE (date unknown). A combination of clinical characteristics and day 7 biomarker concentrations predicts GVHD following hematopoietic cell transplantation from related donors; also presented orally at BMT Tandem Meetings, Salt Lake City, UT. (pp. S138-9). Vol. 19. Accepted, .
  • Vander Lugt MT, Braun TM, Hanash S, Ferrara JLM, Ritz J, Ho VT, Antin JH, Zhang Q, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel D, Reddy P, Paczesny S (date unknown). Plasma ST2 concentrations predict acute GVHD development and non-relapse mortality; also presented orally at BMT Tandem Meetings, Salt Lake City, UT. (pp. S142-3). Vol. 19. Accepted, .
  • Vander Lugt MT, Braun TM, Ferrara JLM, Hanash S, Levine JE, Wang CH, Zhang Q, Chin A, Harris AC, Choi SW, Couriel D, Reddy P, Paczesny S (date unknown). Plasma concentration of suppressor of tumorigenicity 2 (ST2), the IL33 receptor, at initiation of graft versus host disease therapy predicts day 28 response and day 180 survival post-treatment. (pp. S201-2). Vol. 18. Accepted, .
  • Paczesny S, Braun T, Vander Lugt M, Harris A, Fiema B, Hernandez J, Choi SW, Kitko C, Magenau J, Yanik G, Peres EM, Pawarode A, Mineishi S, Whitfield J, Jones D, Couriel DR, Reddy P, Hanash S, Ferrara JLM, Levine JE (date unknown). A three biomarker panel at days 7 and 14 can predict development of grade II-IV acute graft-versus-host disease. (pp. S167). Vol. 17. Accepted, .
  • Harris AC, Ferrara JLM, Levine JE, Braun T, Hogan J, Crawford J, Pitteri S, Wang H, Chin A, Zhang Q, Granger J, Vander Lugt M, Byersdorfer C, Magenau J, Gomez A, Choi S, Kitko C, Yanik G, Peres E,Pawarode A, Mineishi S, Reddy P, Couriel DR, Hanash S, Paczesny S (date unknown). REG3α is a biomarker of gastrointestinal graft-versus-host disease. (pp. S163-4). Vol. 17. Accepted, .
  • Kitko CL, Mineishi S, Braun T, Choi SW, Jones D, Harris A, Khaled Y, Krijanovski O, Paczesny S, Peres E, Yanik G, Whitfield J, Ferrara JL, Levine JE (date unknown). Day7 TNFR1 levels following reduced intensity allogeneic hematopoietic stem cell transplant (HCT) predict for acute GVHD. (pp. S129). Vol. 15. Accepted, .
  • Laetsch TW, Maude SL, Grupp SA, Boyer M, Harris AC, Qayed M, Phillips CL, Pulsipher MA, Bittencourt H, Wood P, Mueller KT, Weng Y, June CH, Levine BL, Hiramatsu H (date unknown). CTL019 Therapy Appears Safe and Effective in Pediatric Patients with Down Syndrome and Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia. (pp. 1280). Vol. 130. Accepted, .
  • Watkins B, Qayed M, Bratrude B, Betz K, Brown M, Rhodes J, Sinclair S, Suessmuth Y, Yu A, Hebert K, Pasquini MC, Choi SW, Davis J, Duncan C, Giller R, Grimley M, Harris AC, Jacobsohn D, Lalefar N, Norkin M, Pulsipher MA, Shenoy S, Blazar B, Langston A, Horan JT, Kean L. (date unknown). T Cell Costimulation Blockade with Abatacept Nearly Eliminates Early Severe Acute Graft Versus Host Disease after HLA-MisMatched (7/8 HLA Matched) Unrelated Donor Transplant, with a Favorable Impact on Disease-Free and Overall Survival. (pp. 212). Vol. 130. Accepted, .
  • Harris AC, Braun T, Byersdorfer CA, Choi SW, Connelly JA, Kitko CL, Yanik G, Levine J (date unknown). Fludarabine combined with myeloablative busulfan (FluBu4) results in reliable engraftment and low transplant-related mortality in pediatric patients. (pp. S223-4). Vol. 21. Accepted, .
  • Magenau J, Westervelt P, McGuirk JP, Khaled SK, Jagasia MH, Rowley S, Kim D, Frey NV, Parameswaran H, Lieland S, Braun T, Schechter-Finkelstein T, Parkin B, Harris AC, Scott BL, DiPersia JF, Forman SJ, Mineishi S (date unknown). Preliminary data from a multi-center study of clofarabine/busulfan conditioning for acute myeloid leukemia not in remission at allogeneic transplantation. (pp. S155-6). Vol. 20. Accepted, .
  • Magenau J, Pawarode A, Couriel DR, Yanik G, Mineishi S, Braun T, Reddy P, Ferrara JLM, Frame D, Choi SW, Harris AC, Kitko CL, Connelly JA, Levine J, Goldstein SC (date unknown). Impact of dose intensification of FluBu2 to FluBu4 on transplant related mortality, relapse, and survival after allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia in Remission. (pp. S226). Vol. 19. Accepted, .
  • Pawarode A, Mineishi S, Braun T, Ferrara JLM, Magenau J, Peres E, Yanik G, Reddy P, Levine JE, Choi SW, Kitko CL, Harris AC, Connelly JA, Goldstein SC, Couriel D (date unknown). Phase 2 study of allogeneic hematopoietic cell transplant (HCT) following intermediate-intensity fludarabine and busulfan X 4 (FluBu4) conditioning for high-risk or advanced multiple myeloma. (pp. S238). Vol. 19. Accepted, .
  • Harris AC, Levine JE (date unknown). Acute Graft-versus-host disease. (pp. 432-7). John Wiley & Sons Publishing. Accepted, .
  • Shyr DC, Homsombath AA, Chan PA, Boyer MA, Harris AC (date unknown). Using CD19 Chimeric Antigen Receptor-T Cell Therapy in a 4-Month-Old Patient with Infantile Acute Lymphoblastic Leukemia. (pp. e28155). Vol. 67. Accepted, .
  • Ferrara JL, Harris AC, Greenson JK, Braun TM, Holler E, Teshima T, Levine JE, Choi SW, Huber E, Landfried K, Akashi K, Vander Lugt M, Reddy P, Chin A, Zhang Q, Hanash S, Paczesny S (date unknown). Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Vol. 118, 6702-8. Accepted, .
  • Fiema B, Harris AC, Gomez A, Pongtornpipat P, Lamiman K, Vander Lugt MT, Paczesny S (date unknown). High throughput sequential ELISA for validation of biomarkers of acute graft-versus-host disease.LID - 10.3791/4247 [doi]LID - 4247 [pii]. Accepted, .
  • Magenau J, Tobai H, Pawarode A, Braun T, Peres E, Reddy P, Kitko C, Choi S, Yanik G, Frame D, Harris A, Erba H, Kujawski L, Elenitoba-Johnson K, Sanks J, Jones D, Paczesny S, Ferrara J, Levine J, Mineishi S (date unknown). Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Vol. 118, 4258-64. Accepted, .
  • Laetsch TW, Myers GD, Baruchel A, Dietz AC, Pulsipher MA, Bittencourt H, Buechner J, De Moerloose B, Davis KL, Nemecek E, Driscoll T, Mechinaud F, Boissel N, Rives S, Bader P, Peters C, Sabnis HS, Grupp SA, Yanik GA, Hiramatsu H, Stefanski HE, Rasouliyan L, Yi L, Shah S, Zhang J, Harris AC (date unknown). Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Vol. 20, 1710-1718. Accepted, .
  • Mody RJ, Wu YM, Lonigro RJ, Cao X, Roychowdhury S, Vats P,Frank KM, Prensner JR, Asangani I, Palanisamy N, Dillman JR, Rabah RM, Kunju LP, Everett J, Raymond VM, Ning Y, Su F, Wang R, Stoffel EM, Innis JW, Roberts JS, Robertson PL, Yanik G, Chamdin A, Connelly JA, Choi S, Harris AC, Kitko C, Rao RJ, Levine JE, Castle VP, Hutchinson RJ, Talpaz M, Robinson DR, Chinnaiyan AM (date unknown). Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. Vol. 314, 913-925. Accepted, .
  • Gatza E, Braun T, Levine JE, Ferrara JL, Zhao S, Wang T, Chang L, Harris A, Pawarode A, Kitko C, Magenau JM, Yanik GA, Couriel DR, Goldstein S, Connelly J, Reddy P, Paczesny S, Choi SW (date unknown). Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Vol. 20, 1426-34. Accepted, .
  • Levine JE, Huber E, Hammer ST, Harris AC, Greenson JK, Braun TM, Ferrara JL, Holler E (date unknown). Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality. Vol. 122, 1505-9. Accepted, .
  • Zhao D, Kim YH, Jeong S, Greenson JK, Chaudhry MS, Hoepting M, Anderson ER, van den Brink MR, Peled JU, Gomes AL, Slingerland AE, Donovan MJ, Harris AC, Levine JE, Ozbek U, Hooper LV, Stappenbeck TS, Ver Heul AM, Lieu TC, Reddy P, Ferrara JL. (date unknown). Survival signal REG3-α prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease. Vol. 128, 4745-5185. Accepted, .
  • Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, Zhang Q, Wong CH, Wang H, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel D, Reddy P, Ferrara JL, Paczesny S (date unknown). ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. Vol. 369, 529-39. Accepted, .
  • Cuvelier GDE, Nemecek ER, Wahlstrom JT, Kitko CL, Lewis VA, Schechter T, Jacobsohn DA, Harris AC, Pulsipher MA, Bittencourt H, Choi SW, Caywood EH, Kasow KA, Bhatia M, Oshrine BR, Flower A, Chaudhury S, Coulter D, Chewning JH, Joyce M, Savaşan S, Pawlowska AB, Megason GC, Mitchell D, Cheerva AC, Lawitschka A, West LJ, Pan B, Al-Hamarneh YN, Halevy A, Schultz KR. (date unknown). Benefits and challenges with diagnosing chronic and late acute GvHD in children using the NIH consensus criteria. Vol. 134, 304-316. Accepted, .
  • Harris AC, Boelens JJ, Ahn KW, Fei M, Abraham A, Artz A, Dvorak C, Frangoul H, Freytes C, Gale RP, Hong S, Lazarus HM, Loren A, Mineishi S, Nishihori T, O'Brien T, Williams K, Pasquini MC, Levine JE (date unknown). Comparison of Pediatric Allogeneic Transplant Outcomes Using Myeloablative Busulfan with Cyclophosphamide or Fludarabine. Vol. 2, 1198-1206. Accepted, .
  • Yanik GA, Mineishi S, Levine JE, Kitko CL, White ES, Vander Lugt MT, Harris AC, Braun T, Cooke KR (date unknown). Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation. Vol. 18, 1044-54. Accepted, .
  • Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, Efebera EF, Hogan WJ, Wolfl M, Qayed M, Hexner EO, Wudhikarn K, Ordermann R, Young R, Shah J, Hartwell MJ, Chaudhry M, Aziz M, Etra A, Yanik GA, Kroger N, Weber D, Chen YB, Nakamura R, Rosler W, Kitko CL, Harris AC, Pulsipher M, Reshef R, Kowalyk S, Morales G, Torres I, Ozbek U, Ferrara JLM, Levine JE (date unknown). MAGIC Biomarkers Predict Long Term Outcomes for Steroid-Resistant Acute GVHD. Vol. 131, 2846-2855. Accepted, .
  • Jacobsohn DA, Loken MR, Fei M, Adams A, Eidenschink-Brodersen L, Logan BR, Ahn KW, Shaw BE, Kletzel M, Olszewski M, Khan S, Meschinchi S, Keating A, Harris A, Teira P, Duerst RE, Margossian SP, Martin PL, Petrovic A, Dvorak CC, Nemecek ER, Boyer MW, Chen AR, Davis JH, Shenoy S, Savasan S, Hudspeth MP, Adams RH, Lewis VA, Kheradpour Am Kasow KA, Gillia AP, Haight AE, Bhatia M, Bambach BJ, Haines HL, Quigg TC, Greiner RJ, Talano J, Delgado DC, Cheerva A, Gowda M, Ahuja S, Ozkaynak M, Mitchell D, Schultz KR, Fry TJ, Loeb DM, Pulsipher MA (date unknown). Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia Pre- and Post-Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. Vol. 24, 2040-2046. Accepted, .
  • Magenau JM, Braun T, Reddy P, Parkin B, Pawarode A, Mineishi S, Choi S, Levine J, Li Y, Yanik G, Kitko C, Churay T, Frame D, Riwes MM, Harris A, Bixby D, Couriel DR, Goldstein SC (date unknown). Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission. Vol. 94, 1033-41. Accepted, .
  • Schultz KR, Kariminia A, Ng B, Abdossamadi S, Lauener M, Nemecek ER, Wahlstrom JT, Kitko CL, Lewis VA, Schechter T, Jacobsohn DA, Harris AC, Pulsipher MA, Bittencourt H, Choi SW, Caywood EH, Kasow KA, Bhatia M, Oshrine BR, Flower A, Chaudhury S, Coulter D, Chewning JH, Joyce M, Savaşan S, Pawlowska AB, Megason GC, Mitchell D, Cheerva AC, Lawitschka A, Azadpour S, Ostroumov E, Subrt P, Halevy A, Mostafavi S, Cuvelier GDE (date unknown). Immune Profile Differences between Chronic GvHD and Late Acute GvHD: Results of the ABLE/PBMTC 1202 Studies. Vol. 135, 1287-1298. Accepted, .
  • Song Y, Magenau J, Li Y, Braun T, Chang L, Bixby D, Hanauer D, Chughtai KA, Gatza E, Couriel D, Goldstein S, Pawarode A, Reddy P, Riwes M, Connelly J, Harris A, Kitko C, Levine J, Yanik G, Parkin B, Choi SW (date unknown). FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. Vol. 51, 511-20. Accepted, .
  • MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, Ho VT, Bolanos-Meade J, Ferrara JL, Jones R, Arora M, Blazar BR, Holtan SG, Jacobsohn D, Pasquini M, Socie G, Antin JH, Levine JE, Weisdorf DJ (date unknown). A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Vol. 21, 761-7. Accepted, .
  • Harris AC, Ferrara JL, Braun TM, Holler E, Teshima T, Levine JE, Choi SW, Landfried K, Akashi K, Vander Lugt M, Couriel DR, Reddy P, Paczesny S (date unknown). Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Vol. 119, 2960-3. Accepted, .
  • Miller HK, Braun TM, Stillwell T, Harris AC, Choi S, Connelly J, Couriel D, Goldstein S, Kitko CL, Magenau J, Pawarode A, Reddy P, Riwes M, Yanik GA, Levine JE. (date unknown). Infectious Risk Following Allogeneic Hematopoietic Cell Transplant Complicated by Acute Graft-Versus-Host Disease. Vol. 23, 522-528. Accepted, .
  • Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, Aziz M, Hogan WJ, Ayuk F, Efebera YA, Hexner EO, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen YB, Devine S, Harris AC, Jagasia M, Kitko CL, Litzow MR, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik GA, Levine JE, Ferrara JL (date unknown). An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. Vol. 2, e89798. Accepted, .
  • Harris AC, Kitko CL, Couriel DR, Braun TM, Choi SW, Magenau J, Mineishi S, Pawarode A, Yanik G, Levine JE (date unknown). Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Vol. 98, 179-84. Accepted, .
  • Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y, Yu A, Sinclair S, Furlan S, Bosinger S, Tkachev V, Rhodes J, Tumlin AG, Narayan A, Cribbin K, Gillespie S, Gooley TA, Pasquini MC, Hebert K, Kapoor U, Rogatko A, Tighiouart M, Kim S, Bresee C, Choi SW, Davis J, Duncan C, Giller R, Grimley M, Harris AC, Jacobsohn D, Lalefar N, Norkin M, Farhadfar N, Pulsipher MA, Shenoy S, Petrovic A, Schultz KR, Yanik GA, Waller EK, Levine JE, Ferrara JL, Blazar BR, Langston A, Horan JT, Kean LS (date unknown). Phase II Trial of Costimulation Blockade with Abatacept for Prevention of Acute GVHD. Accepted, .
  • Pawarode A, Mineishi S, Reddy P, Braun TM, Khaled YA, Choi SW, Magenau JM, Harris AC, Connelly JA, Kitko CL, Parkin BL, Goldstein SC, Yanik GA, Levine JE, Ferrara JL, Couriel DR (date unknown). Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series. Vol. 22, 54-60. Accepted, .
  • Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bonworasate U, Chanswangphuwana C, Efebera YA, Holler E, Litzow M, Ordemann R, Qayed M, Renteria AS, Reshef R, Wölfl M, Chen YB, Goldstein S, Jagasia M, Locatelli F, Mielke S, Porter D, Schechter T, Shekhovtsova Z, Ferrara JLM, Levine JE (date unknown). International, multi-center standardization of acute graft-versus-host disease clinical data collection: a report from the MAGIC consortium. Vol. 22, 4-10. Accepted, .
  • Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H, Magenau J, Weisdorf DJ, Ho VT, Bolanos-Meade J, Alousi AM, Ferrara LM (date unknown). A prognostic score for acute graft-versus-host disease based on biomarkers: a multicenter study. Vol. 2, e21-e29. Accepted, .
  • Laetsch TW, Harris AC (date unknown). Immunoglobulin replacement and quality of life after CAR T-cell therapy (Authors' reply). (pp. e7). Vol. 21. Accepted, .
  • Harris AC, Levine JE, Ferrara JL (date unknown). Have we made progress in the treatment of GVHD?. (pp. 473-8). Vol. 25. Accepted, .
  • Levine JE, Hogan WJ, Harris AC, Litzow MR, Efebera YA, Devine SM, Reshef R, Ferrara JL (date unknown). Improved accuracy of acute graft-versus-host disease staging among multiple centers. (pp. 283-287). Vol. 27. Accepted, .
  • Harris AC, Ferrara JL, Levine JE (date unknown). Advances in predicting acute GVHD. (pp. 288-302). Vol. 160. Accepted, .